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Abstract  
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the UK. This condition 
becomes increasingly prevalent during ageing; 34.1% and 29.8% of males and females respectively, 
over 75 years of age have an underlying cardiovascular problem. The dysregulation of cholesterol 
metabolism is inextricably correlated with cardiovascular health and for this reason low density 
lipoprotein cholesterol (LDL-C) and high density lipoprotein cholesterol (HDL-C) are routinely used as 
biomarkers of cardiovascular disease (CVD) risk. The aim of this work was to use mathematical 
modelling to explore how cholesterol metabolism is affected by the ageing process. To do this we 
updated a previously published whole-body mathematical model of cholesterol metabolism to include 
an additional 96 mechanisms that are fundamental to this biological system. Additional mechanisms 
were added to cholesterol absorption, cholesterol synthesis, reverse cholesterol transport (RCT), bile 
acid synthesis, and their enterohepatic circulation. The sensitivity of the model was explored by the use 
of both local and global parameter scans. In addition, acute cholesterol feeding was used to explore the 
effectiveness of the regulatory mechanisms which are responsible for maintaining whole-body 
cholesterol balance. It was found that our model behaves as a hypo-responder to cholesterol feeding, 
while both the hepatic and intestinal pools of cholesterol increased significantly. The model was also 
used to explore the effects of ageing in tandem with three different CETP genotypes. Ageing in the 
presence of an atheroprotective CETP genotype, conferring low CETP activity, resulted in a 0.6% 
increase in LDL-C. In comparison, ageing with a genotype reflective of high CETP activity, resulted in 
a 1.6% increase in LDL-C. Thus, the model has illustrated the importance of the I405V CETP genotype 
and its potential role in healthy ageing. 
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1.0. Introduction 
Life expectancy is increasing at a phenomenal rate. If one examines life expectancy in the UK 
at the beginning of the 1980s and compares it to the projected value for 2081, then this 
demographic shift in favour of older people is truly emphasized. Males and females born in 
1981, had a life expectancy of 70.9 and 76.9 years respectively, while the projected values for 
2081 are 89.7 and 92.5 years (OFNS, 2013). It is also anticipated that the percentage of 
individuals in the UK over 60 years will double to 22% by 2050, when compared to 2000 (WHO, 
2014). Moreover by 2050 it is anticipated, that the number of individuals >80 years will quadruple 
(WHO, 2014). This increase in life expectancy comes with significant challenges for older 
people. Most significant of these is maintaining health status by remaining disease free. Of the 
diseases which burden older people in the UK, CVD is the leading cause of morbidity (30.3%) 
in individuals ≥60 years of age (Prince et al., 2015). CVD has many risk factors (Appelman et 
al., 2015), however the plasma levels of total cholesterol, LDL-C and HDL-C are long 
established gold standard risk factors for CVD (Appelman et al., 2015). Specifically, rises in both 
total and LDL-C result in an increase in CVD risk, while conversely a rise in HDL-C results in a 
decrease in CVD risk (Austin et al., 1988; Cooney et al., 2009). On a population basis, ageing 
has been shown to result in a rise in both total and LDL-C in males and females (Abbott et al., 
1983). For example, data from the Framingham Study demonstrates there is a gradual rise in 
LDL-C from an initial value of ~100mg/dL in 15-19 year olds (males and females), to 143 and 
159mg/dL in 60-64 year olds, males and females respectively.  Beyond the 6th decade, LDL-C 
levels continue to rise in females, however they marginally decline in males within this 
population (Abbott et al., 1983). The most likely reason for this is that ageing results in the 
dysregulation of whole-body cholesterol metabolism (Mooney and Mc Auley, 2015). Whole-body 
cholesterol metabolism is regulated by a number of factors including cholesterol synthesis, 
intestinal cholesterol absorption, hepatic cholesterol uptake (known as reverse cholesterol 
transport), cholesterol excretion, bile acid production, and deconjugation by intestinal microflora 
and subsequent excretion. Changes to any of these mechanisms can dysregulate cholesterol 
metabolism (Morgan et al., 2016). 
 
The multifaceted nature of cholesterol metabolism, the complexities of its dynamics, and the 
long term impact of the ageing process on its behaviour makes studying this system a challenge 
(Mc Auley and Mooney, 2014). In recent years however, several groups have adopted a 
systems level approach to investigating lipid metabolism (Mc Auley and Mooney, 2015; Mooney 
et al., 2016). The majority of these models have centred on specific metabolic processes, 
including those directed at lipoprotein metabolism (Hubner et al., 2008; Shorten and Upreti, 
2005; Sips et al., 2014), cholesterol biosynthesis (Bhattacharya et al., 2014; Kervizic and 
Corcos, 2008; Mazein et al., 2013; Watterson et al., 2013), reverse cholesterol transport (Lu et 
al., 2014), adipocyte metabolism (Micheloni et al., 2015), hepatocyte metabolism (Jerby et al., 
2010), cholesterol regulatory enzymes (Chapman et al., 2010), whole-body plasma cholesterol 
metabolism (van de Pas et al., 2012) and enterohepatic circulation of bile acids (Mishra et al., 
2014). These models all have noteworthy features and have added to our understanding of lipid 
metabolism. Among the computational systems biology models, the model by Mc Auley et al 
(2012) provides an integrated template for investigating ageing and whole-body cholesterol 
metabolism (Mc Auley et al., 2012). This model is encoded in the systems biology markup 
language (SBML) (Hucka et al., 2004; Hucka et al., 2003), and is part of the curated section in 
the BioModels web site; a repository for models encased in SBML exchange framework (Le 
Novère et al., 2006; Li et al., 2010). This makes the model straightforward to adapt and update. 
The adaptable nature of this model was emphasized recently by Mishra, Somvanshi & 
Venkatesh (2014), who used this model in tandem with another model (Demirezen and Barlas, 
2008). Their combined model included the variables body weight, diet and exercise and they 
analysed the feedback mechanisms of enterohepatic circulation of bile acids; specifically, bile 
acid synthesis, interactions with dietary lipids, and excretion. Despite its integrated nature and 
its focus on ageing, the model by Mc Auley et al. (2012) is lacking several key mechanisms that 
are fundamental to cholesterol metabolism. These key mechanisms include plasma membrane 
receptors, nuclear receptors and a variety of in vivo and intestinal microfloral enzymes. It is 
imperative that these factors are included in any holistic representation of cholesterol 
metabolism. Thus, the aims of this work were fourfold. 1) To mechanistically update the whole-
body mathematical model of cholesterol metabolism by Mc Auley et al. (2012). 2) To use the 
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updated model to explore the role of cholesterol and saturated fat (SFA) feeding on lipoprotein 
profile. 3) To examine the role of age-related alterations to cholesterol metabolism on the 
lipoprotein profile, specifically, cholesterol absorption, LDL-C clearance, and bile acid synthesis 
and subsequent deconjugation. 4) To test the model using pharmacological interventions that 
have been used in vivo to treat hypercholesterolaemia. 
 
2.0. Overview of Cholesterol Metabolism 
Maintaining cholesterol metabolism is a subtle balancing act between the amount of cholesterol 
ingested, absorbed, excreted and synthesised (Mc Auley et al., 2005). Ingested cholesterol, 
exists as esters, and free cholesterol (Iqbal and Hussain, 2009). Esterified cholesterol is 
hydrolysed to free cholesterol by cholesterol ester hydrolase (CEH)/cholesterol esterase/bile 
salt-dependent lipase (BSDL) for micelle incorporation (Ikeda et al., 2002). This facilitates the 
absorption into the jejunocyte by Neimann-Pick C1-Like 1 protein (NPC1L1) endocytosis (Jia et 
al., 2011; Petersen et al., 2008). Internalized free cholesterol is converted to esterified 
cholesterol by acyl coenzyme A: cholesterol acyltransferase 2 (ACAT2). It is then transported 
to apolipoprotein (apo) B-48 to form part of a nascent chylomicron via microsomal triglyceride 
transfer protein (MTP) (Atzel and Wetterau, 1993; Atzel and Wetterau, 1994). Acquisition of apo 
C-II and E converts the chylomicron to a mature chylomicron. On delivery to adipose/muscle 
tissue, apo C-II activates of lipoprotein lipase (LPL), which hydrolysis TAG releasing glycerol 
and FFAs (Kersten, 2014; Olivecrona and Beisiegel, 1997). Hepatocytes then uptake the 
chylomicron remnants via LDLr and low density lipoprotein receptor-related protein (LRP), for 
degradation (Cooper, 1997).  Reverse cholesterol transport (RCT) removes excess cholesterol 
from peripheral tissues and transports it to the liver for excretion in bile or conversion to bile 
acids (Ohashi et al., 2005; Scheibner et al., 1994). RCT begins with the efflux of cholesterol to 
nascent HDLs (ndHDL) (Lund-Katz et al., 2013). Cholesterol efflux can occur via the receptors 
ABC-A1 (He et al., 2015) or scavenger receptor class B type 1 (SR-B1) (Ji et al., 2011), or via 
passive diffusion (Gillotte et al., 1998). Lecithin-cholesterol acyltransferase (LCAT) esterifies the 
incorporated cholesterol, converting the ndHDL to HDL3 (Sorci-Thomas et al., 1990). The 
assembly of 2 small, dense, HDL3 molecules, in the presence of phospholipid transfer protein 
(PLTP), induces the formation of a larger HDL2 molecule (Chirackal Manavalan et al., 2014), 
which can be reversed by hepatic lipase (HL) (Patsch et al., 1987). Cholesterol esters can enter 
the liver directly via the receptor SR-B1, or via CETP, which facilitates the 1:1 exchange of 
cholesterol esters from HDL2 with TAGs from very low density lipoprotein (VLDL) and LDL 
(Zhang et al., 2015). These lipoproteins return the esterified cholesterol to the liver (Brown and 
Goldstein, 1984). LDL can also return cholesterol esters to peripheral tissues (Baigent et al., 
2010). VLDLs and IDLs that haven’t deposited cholesterol esters into the liver, can be 
metabolised via LPL and hormone sensitive lipase (HSL) to LDL.  
 
The enterohepatic circulation of bile acids occurs between 4-12 times per day, but only 5% per 
day are lost in faeces (Gerard, 2013), and of this, 98% is in the unconjugated form (Batta et al., 
1999). Although preferentially hydrolysing glyco-conjugated bile acids, both glyco- and tauro- 
conjugated bile acids can be converted to unconjugated bile acids whilst in the intestinal lumen 
by the hydrolysis of the amine bond, and removal of glycine or taurine by bacterial bile salt 
hydrolase (BSH) (Jarocki et al., 2014). Certain intestinal microflora have the ability to produce 
BSH, but Lactobacillus species are responsible for 86% of the BSH activity in the ileum, and 
74% in the caecum (Tannock et al., 1989). The probiotic administration of BSH-producing 
strains can lead to a decrease of 63.2% in plasma LDL-C levels. This is due to the increase in 
excreted bile acids, leading to enhanced de novo synthesis of bile acids from cholesterol, to 
replace those excreted. Furthermore, there is a decrease in cholesterol solubility due to an 
increase in the proportion of unconjugated bile acids. In addition, there is a rise in the ratio of 
propionate to acetate (Begley et al., 2006; Guo and Li, 2013). However, this treatment strategy 
is controversial as evidence suggests that the byproducts of unconjugated bile acids have been 
associated with the dysregulation of mucosal functioning (Ajouz et al., 2014; Baptissart et al., 
2013). 
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3.0. How Cholesterol Metabolism changes with Age 
It has been consistently shown that LDL-C increases with age in both males and females across 
different population groups (Abbott et al., 1983; Yang et al., 2012). A number of mechanisms 
have been implicated in this age-related rise in LDL-C. For example, it has been suggested that 
an increase in the absorption of dietary cholesterol is one of the factors responsible for the 
increase of serum LDL-C with age (Duan et al., 2006; Hollander and Morgan, 1979). Murine 
models demonstrate that this increase in cholesterol absorption is correlated with the age-
related increase in the apical membrane receptor NPC1L1 in the duodenum and jejunum (Duan 
et al., 2006; Hollander and Morgan, 1979). Ageing resulted in a 17% increase in cholesterol 
absorption in one murine model due to a significant increase in NPC1L1 mRNA in both the 
duodenum and jejunum (Duan et al., 2006). The receptor NPC1L1 plays a vital role in the 
absorption of dietary cholesterol. Thus, inhibiting NPC1L1 with ezetimibe is one strategy that 
has been adopted in the treatment of hypercholesterolaemia (Dujovne et al., 2002). Another 
mechanism that has been associated with the dysregulation of cholesterol metabolism is a 
decrease in LDLr numbers and/or activity. LDLr is responsible for the uptake of circulating LDL-
C from the plasma. LDLr therefore lowers the plasma LDL-C levels and reduces CVD risk 
(Brown and Goldstein, 1984). The age-related decline in LDLr, results in a reduction in LDL 
clearance, thus raising the plasma LDL-C levels (Millar et al., 1995). This decline in LDLr with 
age could be due to the age-related increase in proprotein convertase subtilisin kexin-9 
(PCSK9), a serine protease associated with LDLr degradation (Cui et al., 2010). Additionally, 
this could be due to the decreased demand for cholesterol for the de novo synthesis of bile acid, 
due to the age-related decrease in bile acid synthesis (Ericsson et al., 1991). A decline in bile 
acid synthesis and hepatic expression of CYP7A1 have been shown to be correlated with ageing 
in human subjects (Bertolotti et al., 2007). This decreases cholesterol utilisation for the de novo 
synthesis of bile acids (Bertolotti et al., 2007). This is supported by Bertolotti et al. (1993) who 
carried out a linear regression analysis which estimated that the amount of cholesterol 
undergoing the CYP7A1 regulated reaction in humans decreases by 60mg per day, every 10 
years (Bertolotti et al., 1993). It is also possible that the down regulation of CYP7AI is due to the 
age related decline of growth hormone (GH), as illustrated by rodent studies (Parini et al., 1999). 
Similar studies have also illustrated that sex hormones play a role in the decline of CYP7AI, as 
gender differences are often observed. For example, aged female rodents often have an 
increased concentration of serum bile acids, whereas levels remain constant in males with age 
(Fu et al., 2012). This is in addition to alterations to the composition of bile acids (Trautwein et 
al., 1999). Gut microflora are also affected by the ageing process. Levels and species diversity 
of Lactobacillus and Bifidobacterium species are consistently lower in older people than younger 
human adults (Hopkins and Macfarlane, 2002; Hopkins et al., 2001). These species are well 
documented for their ability to produce the enzyme BSH, which is responsible for the 
deconjugation of bile acids in the small intestine (Tanaka et al., 1999). This decrease in BSH-
positive species leads to a decrease in bile acid excretion and thus a decrease in cholesterol 
utilisation for the de novo synthesis of replacement bile acids (Uchida et al., 1996). This could 
be one cause of the increase in LDL-C with age. Interestingly, supplementation with probiotic 
strains in elderly rodent populations has been shown to reduce LDL-C levels (Al-Sheraji et al., 
2012) as well as improve gut health (Tuohy et al., 2003) and increase immunity in human 
subjects (Moro-Garcia et al., 2013). Mutations in the gene coding for CETP have also been 
linked to healthy ageing. CETP mediates the transport of cholesterol esters from HDL to LDL 
and VLDL. Mutation to the CETP gene has been associated with longevity in Ashkenazi Jews 
(Atzmon et al., 2005; Barzilai et al., 2003). The amino acid substitution of 405 isoleucine to 
valine (I405V) in the CETP gene results in a lower serum CETP concentration and subsequently 
significantly larger LDL and HDL. The CETP I405V genotype is associated with a reduced 
prevalence of CVD, diabetes mellitus, and hypertension, possibly contributing to the exceptional 
longevity observed in these individuals (Atzmon et al., 2005; Barzilai et al., 2003). The assertion 
that reduced CETP levels convey a protective phenotype for healthy ageing, has led to 
investigations into the use of CETP inhibitors as a therapeutic strategy for the treatment of 
hypercholesterolaemia. For example, it has been recently revealed that in phase II clinical trials 
the CETP inhibitor TA-8995 decreased LDL-C by 27.4% with a 1mg daily dose, with minimal 
adverse effects (Hovingh et al., 2015). Therefore, with our updated model, there was a clear 
emphasis on these aspects of lipid metabolism. 
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4.0. Methods 
 
4.1. Diagrammatic Representations of Whole-Body Cholesterol Metabolism  
Our updated model consists of 8 compartments which are: 1) dietary intake, 2) intestinal lumen, 
3) jejunocytes, 4) ileocytes, 5) hepatic tissue, 6) blood, 7) peripheral tissue and 8) excreted 
(Figure 1). Figures 1 – 3, were created using systems biology graphical notation (SBGN). SBGN 
is a graphical representation modelling format designed to be employed as a universal 
framework for the construction of diagrammatic representations of biological or other processes, 
to allow easy recognition of each species and process (Le Novere et al., 2009). Figure 1 is an 
adaptation of the previous SBGN diagram generated by Mc Auley et al. (2012). The SBGN 
diagrams were developed with VANTED (Version 2.2.1, http://vanted.ipk-gatersleben.de/, 
http://www.sbgn.org/Main_Page) (Rohn et al., 2012). To incorporate the additional information 
into the SBGN diagram, the compartment previously referred to as ‘intestine’ was divided into 3 
sub-compartments, ‘intestinal lumen’, ‘jejunocytes’ and ‘ileocytes’. The role of several key 
processes, receptors and enzymes could then be incorporated. These include the differentiation 
of dietary free and esterified cholesterol, bile acid micelle formation for the uptake of free 
cholesterol via the NPC1L1 receptor, cholesterol esterification in the jejunum, chylomicron 
transport, and bile acid reabsorption. The mechanisms underpinning RCT were expanded from 
those represented in the original model. The enzymes PLPT, HL, LCAT and CETP and their 
roles in HDL subtype composition and cholesterol transport were included. Following this, 
additional receptors were incorporated into the peripheral tissue, hepatic tissue, and the newly 
formed ileocytes compartments to further elucidate the transport mechanisms of cholesterol, 
lipoproteins and bile acids. Next, cholesterol biosynthesis was converted from a 1 step process 
in the Mc Auley et al. (2012) model to an 18 step process. Overall, cholesterol biosynthesis has 
significantly more steps than this. However, the rationale for abstracting to an 18 step reaction 
system is as follows. The first 13 steps of cholesterol biosynthesis are well characterised 
(Liscum, 2008). The latter reactions in this process remain poorly characterised. Therefore, the 
reactions that were included are those that are central to the pathway and are well delineated. 
Due to the size and complexity of this reaction network, a separate SBGN diagram was 
developed to illustrate this component of the model (Figure 2). In our overall diagrammatic 
representation of the model (Figure 1) these reactions are simplified to 3 source and sink glyphs 
labelled *a, in the jejunocytes, hepatic and peripheral tissue compartments. Finally, the de novo 
synthesis of bile acids from hepatic cholesterol was converted from a 1 step process to a 15 
step process, and similar to the cholesterol synthesis pathway, was too detailed to be 
represented fully in Figure 1. Bile acid synthesis is therefore represented by the source and sink 
glyph labelled *b in Figure 1, and is fully illustrated in Figure 3. The reactions outlined in Figure 
3 are derived from various sources. In essence they are a summary of the processes that are 
well characterised. Some well characterised steps are excluded from the summary to reduce 
the process diagram size, and for clarity. For example, following the chain shortening of 4-
cholesten-7α, 12α- diol-3-one by CYP27AI further modification by SLC27A5 (EC 6.2.1.7), 
ACOX2 (EC 1.17.99.3), HSD1724 (EC 1.1.135) and SCP2 (EC 2.3.1.176), occurs before cholic 
acid formation. There is ambiguity surrounding the re-entry of compounds involved in the 
alternative pathways to the final steps before the formation of cholic or deoxycholic acid resulted 
in gaps of knowledge. For this reason, there are process glyphs that represent a series of 
uncertain steps. 
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Figure 1. SBGN diagram of mathematical model of whole-body cholesterol metabolism. The diagram details the transport of cholesterol, bile acids 20 
and lipoproteins through cholesterol absorption, lipoprotein metabolism, RCT and enterohepatic circulation. For abbreviations see Table A.2. Round 21 
arrow head represent the target of a catalytic enzyme, represented as blue rounded rectangles. Arrows represent flux. Hatched process nodes represent omitted 22 
processes. T shaped arrows represent inhibition. The Greek symbol theta represents synthesis/degradation. a* cholesterol synthesis (see Figure 2), 23 
b* bile acid synthesis (see Figure 3).24 
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Figure 2. Cholesterol biosynthesis. Synthesis of 
cholesterol from acetyl CoA via intermediates HMG CoA, 
mevalonate, squalene and lanosterol. See Table A.2 for 
abbreviations. Round arrow heads represent the target 
of a catalytic enzyme, represented as blue rounded 
rectangles. Arrows represent flux. Hatched process 
nodes represent omitted processes. The Greek 
symbol theta represents synthesis. Acetoacetyl CoA 
thiolase catalyses the interconversion of acetyl CoA and 
acetoacetyl CoA. Acetyl CoA and acetoacetyl CoA 
undergo a condensation reaction to form 3-hydroxy-3-
methylglutaryl-coenzyme A (HMG CoA). HMG CoA is then 
converted by HMG CoA reductase to mevalonate. 
Phosphorylation of mevalonate forms mevalonate-5P, 
which is further phosphorylated to mevalonate-5PP. 
Decarboxylation and dehydration of mevalonate-5PP 
forms isopentenyl-PP (IPP), which converts to its isoform 
dimethylallyl-PP (DMAPP). DMAPP reacts with IPP to 
create geranyl-PP. Further condensation and the addition 
of another IPP creates farnesyl-PP. Condensation of 2 
farnesyl-PP molecules forms squalene, which is converted 
to squalene epoxide before undergoing cyclisation to form 
lanosterol. A series of reactions, including the branching of 
7-dehydrodesmosterol to either desmosterol or 7-
dehydrocholesterol, both of which can then be converted 
to cholesterol.  
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Figure 3. Bile Acid Synthesis.  
Classical Pathway: Hydroxylation of 
cholesterol creates 7α- 
hydroxycholesterol. Subsequent 
modification of the sterol ring forms 
7α-hydroxy-5β-cholesten-3-one 
before the classical pathway splits, to 
enable the formation of either cholic 
acid (CA) or chenodeoxycholic acid 
(CDCA). For the formation of cholic 
acid, modification of the sterol ring by 
12α-hydroxylase (CYP7B1) must 
occur before further modification. 
The side chain of 5β-cholesten-7α, 
12α- diol-3-one is then acted upon by 
a series of oxidation steps leading to 
its shortening. Further modification 
by several enzymes then takes place 
to form CA.  The same steps, 
although in the absence of CYP8B1, 
are undergone in the other route of 
the classical pathway, to form CDCA. 
Alternative Pathway: Side chain 
shortening occurs first in the 
alternative pathway creating 27α- 
hydroxycholesterol, before 
hydroxylation creates 3β-7α-
dihydroxy-5-cholestenoate. 
HSD3B7, CYP8B1 and AKR1D1 
modification of the sterol ring can 
then occur, and upon further 
alteration, CA and CDCA can then be 
formed. This is followed by 
conjugation of 98% of these bile 
acids. They are they effluxed from the 
hepatocyte primarily by bile salt 
export pump (BSEP) in the rate 
limiting step of bile acid circulation. 
See Table A.2 for abbreviations. Round 
arrow head represent the target of 
catalytic enzyme, represented as 
blue rounded rectangles. Arrows 
represent flux. Hatched process 
nodes represent omitted processes.  
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4.2. Model Assembly and Parameterisation 
 
The SBML for the original model was downloaded from the BioModels database(Juty et al., 
2015) (https://www.ebi.ac.uk/biomodels-main/, BIOMD0000000434). It was then imported into 
Version 4.14.89 of Copasi (Hoops et al., 2006). Within Copasi the model was then reassembled. 
The original model contained 48 species. The updated version now contains 144 species 
including the 4 species used as counters for the event reactions (Table A.3). The first processes 
to be added were the ingestion of free cholesterol and cholesterol esters. To represent these 
reactions we defined a number of new species, and parameters and then introduced two SBML 
events for each species. An event in SBML is a reaction which is activated at a particular point 
in time and which causes a change in the value of a species concentration, compartment size, 
or parameter. In this case, the rationale for including events was to represent the ingestion of 
cholesterol every 8 hours. This was more biologically realistic than the single reaction which 
represented this process previously. The events were defined in using the syntax outlined in 
Table A.1. Events stimulated the intake of both free cholesterol and cholesterol esters. The 
creation of the events reflected the intake of a meal every 8 hours. Following the assembly of 
the events, the entry of dietary esterified cholesterol into the intestinal lumen 3 times a day was 
deterministically simulated (Figure 4A). Once in the intestinal lumen, esterified cholesterol is 
converted to free cholesterol for entry into the jejunocytes. Figure 4B illustrates how the level 
of free cholesterol in the jejunocyte was affected by the entry of this converted free cholesterol. 
This is in addition to the 88.667mg of free cholesterol that is also ingested 3 times a day, and 
the 1000mg/day of biliary cholesterol effluxed back into the lumen from the liver. Within the 
model, free cholesterol contained in the jejunum fluctuated. Initial steady state values for free 
and esterified cholesterol in the hepatic or peripheral tissues were calculated based on the 
experimental data in Table 1 (Figure 4C). Other species were calculated in a similar way, 
utilising tissue mass and molecular mass. The initial steady state levels of many other 
intermediate species were assumed. Each value is in mg/compartment. Table A.2 provides the 
details of the species and their abbreviations, while Table A.3 provides details of over 144 
kinetic based reactions which in total make up the new version of the model. To summarise the 
kinetics, the model includes 37 reactions which are derived using the law of mass action, 58 
reactions informed by Michaelis-Menten kinetics, 6 reversible reactions informed by Michaelis-
Menten kinetics, 9 bi, 3 ping pong bi-bi kinetic reactions, and 31 rate laws that were either part 
of the old model or developed during its adaptation. Each functional form is underpinned by the 
experimental literature, and examples of all the functional forms are provided within the ordinary 
differential equations (Appendix B). In order to parameterise the kinetic reactions summarised 
in Table A.3, firstly a comprehensive search of the enzyme functional data repository, BRENDA 
was conducted (http://www.brenda-enzymes.org/) (Chang et al., 2015). Many of the enzymes 
identified within BRENDA had a wide range of values. Suitable values were selected based on 
considering the biological source of the kinetic information. Some of the model parameters could 
not be located within BRENDA, therefore to obtain these parameters, literature searches were 
conducted using PubMed, Science Direct and Google Scholar. The source of each parameter 
is indicated in column 4 of Table A.4. For a number of parameters, no kinetic information could 
be obtained, therefore several assumptions were used, the details of these are also given in 
table A.4. The model was tuned until an ‘optimal’ set of parameters was obtained, which 
reflected the steady state values of key model outputs 
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Table 1. Data used to calculate initial values of cholesterol in each compartment. See table A.2 for 
abbreviations. 
Species Concentration 
Molecular 
mass 
Location 
Mass (kg) 
Calculated mass 
(mg) 
Reference 
      
HFC 67.1nmol/mg 386.66 
1.5 
38,917.329 
Mc Auley et al. (2012) & 
van de Pas et al. (2012) 
HCE 18.5nmol/mg 649.08 18,011.97 
PFC 399.9mg/kg - 
64.8 
25,913.52 
PCE 65.1mg/kg - 4,218.48 
      
 
Utilising a plasma volume of 2.79L (van de Pas et al., 2012), the initial steady state values of 
VLDL-C, LDL-C and HDL-C (Sharma et al., 2010), could be converted to mg/plasma (Table 2). 
Lipoprotein values were converted back to mg/dL for analysis. When the model was simulated, 
VLDL-C, LDL-C and mean HDL-C values were consistent with these literature values (Figure 
4D). Mean HDL-C was calculated from HDL2 and HDL3 and ndHDL-C subfractions. Cholesterol 
and unconjugated bile acids were steadily excreted at a rate of 0.1 and 0.05mg/hour respectively 
(Figure 4E). The initial steady state values for bile acids were assumed. For bile acids contained 
in the hepatic tissue, a value of 220mg was utilised for those conjugated (HCBA). A value of 
180mg was assigned to represent the unconjugated proportion (HUBA), and a value of 200mg 
was chosen to represent HUBA-CoA. Within the ileocytes, a value of 50mg was utilised for both 
the conjugated and unconjugated forms (ICBA and IUBA). Within the intestinal lumen a steady 
state value of 200mg was assumed to represent conjugated bile acids, while a value of 50mg 
represented the steady state level of unconjugated bile acids (LCBA and LUBA). Levels 
remained constant over time (Figure 4F). 
 
 
Table 2. Data used to calculate the initial values of lipoproteins. See Table A.2 for abbreviations. 
Lipoprotein 
Concentration 
(mg/dL) 
Plasma Volume 
(L) 
Calculated mass 
(mg) 
Reference 
     
VLDL-C 34 
2.79 
948.6 
Sharma et al. (2010) & van 
de Pas et al. (2012) 
LDL-C 115 3,208.5 
HDL-C 44 1,227.6 
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Figure 4. Model Outputs of A) ingestion of esterified cholesterol, B) jejunocyte pool of free 
cholesterol C) hepatic and peripheral pools of free and esterified cholesterol, D) lipoprotein 
profile E) excreted cholesterol and unconjugated bile acids and F) hepatic, ileocyte and intestinal 
lumen pools of conjugated and unconjugated bile acids. For D) mean HDL-C calculated from 
HDL2, HDL3 and ndHDL-C. 
 
 
5.0. Results 
 
5.1. Initial Examination of the Model  
Initial simulations were performed to compare model output with our previous model. Figure 5 
illustrates how several key variables compare to the original model. Over a 15 day period it was 
found that the average concentration of LDL-C, mean HDL-C and total cholesterol reduced by 
11%, 20% and 0.6% respectively, when compared to the original model. Mean HDL-C was 
calculated from HDL2, HDL3 and ndHDL-C. In contrast, IDL-C and VLDL-C increased by 33% 
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and 67% respectively in the updated model. The LDL-C:HDL-C ratio increased slightly from 
2.52:1 in the original model to 2.77:1 in the updated model. Both of these ratios however are in 
line with current recommendations. A ratio <3.0:1 and <2.5:1 is optimal for males and females 
respectively, to reduce the risk of CVD onset (Millan et al., 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Comparison of the lipoprotein profile from the original and updated model. Model run for 15 
days or equivalent (21,600 minutes). Circle markers represent the model output from the updated 
model. Triangle markers represent the lipoprotein profile from the Mc Auley et al. (2012) model. HDL-
C from the updated model is the mean average of HDL2, HDL3 and ndHDL-C. 
 
 
5.2. Dietary Cholesterol Ingestion 
 
Individual differences exist in cholesterol metabolism from one individual to the next (Herron et 
al., 2003). This is emphasised by DC feeding studies which demonstrate notable differences in 
the response to DC from one individual to individual. Herron et al. (2003) demonstrated that 
hypo-responders could ingest ~640mg/day of cholesterol with no effect on LDL-C or HDL-C 
levels. In contrast, hyper-responders exhibited a 30% increase in LDL-C and an 8% increase in 
HDL-C (Herron et al., 2003). To determine if the model behaves as a hypo- or hyper-responder, 
fold increases of 0.5, 1, 2, and 3 were applied to both ingested free and esterified DC. To do 
this the events for DC ingestion were modified. For the 0.5-fold analysis, 44.335mg of free 
cholesterol and 6.3335mg of esterified cholesterol were ingested 3 times a day. Whereas an 
increase to 266.001mg of free cholesterol and 38.001mg of esterified cholesterol was ingested 
3 times a day for a 3-fold dietary increase. A 2-fold increase in DC resulted in an increase of 
0.0012% (0.0014mg/dL) in LDL-C, (>1000 hours). No change in mean HDL-C levels were 
observed (data not shown). A 2-fold increase in DC resulted in a 23.7% increase in HFC, and a 
negligible increase of 0.0002% in HCE. No difference in PFC or PCE was observed (Figure 
6A). 
 
 
5.3. Comparison with Clinical data  
Both the original and updated models were compared to clinical data from a DC feeding study 
(Figure 6B). After a comprehensive literature search in this area, the most suitable time course 
data that could be obtained was from a healthy 31 year old normocholesterolaemic male that 
underwent an 11 week high cholesterol diet (1000mg/day) (Lin and Connor, 1980). The purpose 
of using this data, which clearly shows a hyper-response to DC, was to provide a comparison 
between this and our models. To compare the model to the clinical data, the intake of cholesterol 
was raised to 1000mg per day, and baseline LDL-C was reduced to 66.32mg/dL. To recreate a 
1000mg/day cholesterol intake, the events were altered to reflect an intake of 291.667 FC and 
41.667mg CE 3 times a day. Lin and Connor (1980) did not report LDL-C or HDL-C values, 
therefore LDL-C was calculated from total cholesterol and triglyceride values using the equation 
below, in which LDL-C can be calculated in the absence of HDL-C data (Anandaraja et al., 
2005).  
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𝐶𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 𝐿𝐷𝐿‒ 𝐶 =  (0.9 𝑥 𝑇𝑜𝑡𝑎𝑙 𝐶ℎ𝑜𝑙𝑒𝑠𝑡𝑒𝑟𝑜𝑙) −
0.9 𝑥 𝑡𝑟𝑖𝑔𝑙𝑦𝑐𝑒𝑟𝑖𝑑𝑒𝑠
5
− 28 
 
When the daily rate of cholesterol ingestion was raised, LDL-C increased from an initial value 
of 66.32mg/dL, to a steady state value of ~115mg/dL after one week. It is important to note this 
is the behaviour of LDL-C regardless of the rate of dietary cholesterol ingestion. This finding 
contrasts with the original model’s response during this feeding regime, where LDL-C continues 
to rise after week one. It is feasible the behaviour of the updated model is biologically plausible, 
as several decades of experimental work in this area have suggested that cholesterol 
metabolism is tightly regulated in the majority of individuals, with hypo-responders known to 
exhibit a negligible lipoprotein response (Herron et al., 2003; Jones et al., 1996; Quintao et al., 
1971). Consequently, it was important to establish which regulatory mechanisms responded 
effectively in the model to inhibit a rise in lipoprotein cholesterol. After examining the simulation 
data it was found a key regulatory mechanism which adapted to this increase in DC was 
cholesterol excretion (EFC). EFC increased by 25.1% by the end of the 11 week period. In 
addition to the compensatory effect of excreted cholesterol, intestinal and hepatic cholesterol 
also increased. It was found high DC resulted in the pool of CE in the intestinal lumen (LCE) 
increasing to 5.97mg after 11 weeks. This contrasted with a value of 0.15mg after a ‘normal’ 
cholesterol feeding regime over the same time period. LFC also increased by 4.75% as a result 
of this simulation. The amount of absorbed cholesterol, in the jejunocytes also increased; JFC 
and JCE levels were 24.41 and 0.03% higher respectively after the cholesterol feeding. In 
addition, HFC increased by 85.25%, while the increase in HCE was negligible (0.0005%). Bile 
acid levels and LDLr activity/number were unaffected during cholesterol feeding, which could 
account for the substantial cholesterol accumulation within the hepatic tissue, and marginal 
LDL-C response.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Cholesterol Ingestion Analysis. A) Response of LDL-C and cholesterol pools in the updated 
model to fold-change increases in dietary cholesterol after 1000 hours. HFC, hepatic free cholesterol; 
PFC, peripheral free cholesterol (left axis); HCE, hepatic cholesterol esters; PCE, peripheral cholesterol 
esters; and LDL-C (right axis). B) Goodness of fit of model to clinical data. Comparison of LDL-C 
concentration in response to simulated cholesterol feeding in the Mc Auley et al. (2012), and the 
updated model, with a human cholesterol feeding study. A 1000mg dose of cholesterol was ingested 
per day by a human subject and induced in both models for an 11 week trial period and the LDL-C 
monitored. Baseline LDL-C of both models was set at 66.32mg/dL to match clinical data. Black line 
represents updated model the green line represents the Mc Auley et al. (2012) model, and the orange 
bar represents the LDL-C response to cholesterol feeding in a human subject (Lin and Connor, 1980).   
 
5.4. Acute daily ingestion of saturated fat 
Diets high in SFA are associated with raised plasma cholesterol levels. High levels of SFA lead 
to an increase in LDL-C by three possible mechanisms. 1) LDL-C clearance rate, as SFA 
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supresses LDLr activity (Woollett et al., 1992). 2) There is an increase in the rate of cholesterol 
synthesis (Jones et al., 1994). 3) Modulation of RCT occurs (Berard et al., 2004; Jansen et al., 
2000). RCT is affected in 2 ways. Firstly, CETP is upregulated, thus transporting esterified 
cholesterol from HDL-C to LDL-C and VLDL-C at an increased rate (Jansen et al., 2000). 
Secondly, LCAT is inhibited which reduces the esterification of cholesterol in HDL-C. This 
reduces the concentration gradient for the transfer of cholesterol from the peripheral tissues to 
HDL. To replicate SFA intake variations, 7 parameters were altered simultaneously (Table 3). 
This analysis resulted in increases to LDL-C, HCE and PCE levels, whereas HDL-C decreased 
(Figure 7). LDL-C, HCE, and PCE increased 1.7, 0.4 and 0.5% respectively for the 2 fold-
analysis. There was no effect on hepatic and peripheral free cholesterol (HFC and PFC) after 
1000 hours. 
 
 
Table 3. Summary of parameters involved in fold analysis of SFA intake. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Fold change analysis of dietary SFA. The percentage change in LDL-C, HDL-C (left axis), 
HCE and PCE (right axis) monitored with fold changes to SFA intake. A total of 7 parameters were 
modified in the fold change analysis to represent an equivalent change in dietary SFA. To represent an 
increase in dietary SFA, increases to the rate of LDLr degradation, cholesterol synthesis and CETP 
mediated transport, and decreases to the LCAT mediated cholesterol esterification were conducted. 
Measurements recorded at 1000 hours. 
 
  
Reaction Parameter 
Fold Change 
0.5 1 2 3 
       
36 LCAT activity Khdl3 8 x 10-4 4 x 10-4 2 x 10-4 1.33 x 10-4 
39 CETP mediated transfer to 
VLDL 
Kcetp2 5 x 10-8 1 x 10-7 2 x 10-7 3 x 10-7 
40 CETP mediated transfer to 
LDL 
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60 LDLr degradation K1 5 x 10-8 1 x 10-7 2 x 10-7 3 x 10-7 
78 Hepatic acetyl CoA synthesis K1 0.5 1 2 3 
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5.5. Local Sensitivity Analysis  
To gain further insight into the robustness of the model a sensitivity analysis (SA) was 
performed. A robust model is resilient to relatively small perturbations in parameter values. 
Therefore given the lack of sensitivity of our model during our initial investigations the aim of the 
SA was to investigate the effect of both local and global parameter changes on model outputs, 
in particular LDL-C, and to identify critical parameter inputs. We firstly completed a local SA and 
calculated the sensitivity coefficients (Si) for each of the parameters of the model. To do this we 
removed the discrete feeding events and replaced them with a continuous feed for both DC and 
DFC. Appendix C gives the percentage change in output values for a 1% change in each of 
the 266 model parameters and ranks them by sensitivity, while Figure 8 presents the 10 most 
sensitive parameters of this analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. The 10 most sensitive parameters. Si, sensitivity index, percent change in LDL-C for 
a 1% change in model parameters; R, reaction. See Table A.3 for reaction details. 
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5.6. Global analysis 
 
Given the uncertainty surrounding a number of the parameter values, especially those 
associated with the less well characterised aspects of cholesterol metabolism, it is apparent that 
any inferences from our local sensitivity analysis should be interpreted with caution. Therefore, 
we deemed that it would be appropriate to conduct a global sensitivity analysis. A global 
sensitivity analysis attempts to mitigate this problem by examining model parameters in broader 
regions of parameter space. The rate constant for hepatic LDLr degradation was selected as 
our parameter of interest for the global scan (reaction 60 in Table A.3). This parameter was 
selected as the experimental literature suggests this is an important parameter for maintaining 
cholesterol homeostasis, and the reduction in hepatic LDLr numbers and/or activity has been 
associated with intrinsic ageing (Field and Gibbons, 2000). Furthermore, of the mechanisms 
associated with ageing, this parameter was most sensitive (see appendix C). As no priori data 
was available on this parameter, it was determined that an appropriate sampling choice would 
be based on a uniform probability density function (Marino et al., 2008). Figure 9 presents the 
results from a global sensitivity analysis, where random samples were taken over a range of a 
2 fold increase and decrease in the default value for this rate constant, with A) all “known” 
parameters scanned and unknown parameters fixed, B) all unknown parameters scanned and 
“known” parameters fixed, and C) all parameters scanned simultaneously, at 250 hours 
(N=500). See appendix C for a list of the scanned parameters for each of these simulations. 
Each scanned parameter had random samples taken between a 2 fold increase and decrease 
of its default value. The variability of LDL-C was small when 151 “known” parameters were 
scanned, and 113 unknown parameters remained fixed. The results show that LDL-C varied 
~2mg/dL for any value of the rate constant for hepatic LDLr degradation between a 2 fold 
increase and decrease from its default value (Figure 9A). In contrast, LDL-C varied by ~500mg 
when the “known” parameters were fixed and the unknown parameters scanned. Consequently 
the relationship between hepatic LDLr degradation and LDL-C was lost (Figure 9B). When all 
266 parameters were scanned (including the 2 parameters used for the counter reactions for 
DFC and DCE intake), the range of LDL-C values remained similar. A marginal further reduction 
in R2 was also observed (Figure 9C). The significant difference in LDL-C variation when 
scanning parameters with well characterised kinetics versus parameters with assumed 
parameter values suggests the unknown parameters influence the behaviour of the model 
significantly. Moreover, the large range in LDL-C when unknown parameters were scanned, 
reinforces our finding from the local sensitivity scan, that parameters with assumed kinetics were 
most sensitive.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Global sensitivity analysis of parameter K1, hepatic LDLr degradation. Role of 
parameter K1 for hepatic LDLr degradation (reaction 60) with A) all unknown, assumed, and 
adapted parameters fixed, B) all “known” parameters fixed, and C) all parameters scanned. 
Non-fixed parameters were analysed between a 2-fold increase and decrease of that parameter 
value; calculated at 250 hours, N=500. R2 = Coefficient of determination. See section 5.6 for 
details of each figure. 
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5.7. Ageing 
As previously discussed, the ageing process affects many of the key mechanisms involved in 
cholesterol metabolism. Specifically, there is 1) an age-related decline in hepatic LDLr and 
subsequent reduction in LDL-C clearance (Millar et al., 1995), 2) an increase in cholesterol 
absorption (Duan et al., 2006), 3) a decline of BSH-positive intestinal microflora, such 
Lactobacillus and Bifidobacterium species (Hopkins and Macfarlane, 2002), and 4) a decline in 
bile acid synthesis (Bertolotti et al., 2007). To represent the ageing process, 4 parameters were 
modified. These modifications were a 2-fold decrease to the rate of NPC1L1 degradation, 
bacterial deconjugation, and CYP7AI activity. In addition, the rate of LDLr degradation was 
increased 2-fold (Table 4). The inverse of this analysis, was assumed to represent a young 
individual. 
 
Table 4. Summary of parameters involved in the ageing analysis. 
 
 
By simultaneously conducting a 2-fold decrease to the parameters Kcetp1 and Kcept2, a CETP 
genotype such as I405V could also be replicated (reactions 40 and 39 respectively, Table A.3). 
A-2 fold increase in Kcept1 and Kcept2 was also conducted to replicate a genotype reflective of a 
genetic predisposition for atherogenesis. These CETP genotypes were applied to each age 
category and LDL-C was recorded after 1000 hours (Figure 10). The ageing process resulted 
in an increased LDL-C for all CETP genotypes. The ageing process, in the presence of the 
genotype representing high CETP activity, resulted in a 1.6% increase in LDL-C. Similarly, the 
normal CETP genotype also produced a 1.6% increase in LDL-C with ageing. The CETP 1405V 
genotype however resulted in a less significant rise (0.6%) in LDL-C with the ageing process. 
By contrasting the genotypes within each age category, the beneficial effects of the CETP I405V 
genotype were further substantiated. This advantageous genotype was more obvious in the 
aged category than the youth and normal categories. A 1.63% reduction in LDL-C was observed 
in the aged category, compared to a 0.64% reduction in both the normal and youth category. 
On the contrary, the effect of a genetic predisposition to atherosclerosis, was more apparent in 
the youth and normal categories, than the aged category, although this was negligible (0.617, 
0.617 and 0.616% respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction Parameter 
Age group 
Young Default Old 
      
45 Bile acid Deconjugation Vmax 1 x 10-5 5 x 10-6 2.5 x 10-6 
54 NPC1L1 degradation K1 2 x 10-7 1 x 10-7 5 x 10-8 
60 LDLr degradation K1 5 x 10-8 1 x 10-7 2 x 10-7 
132 CYP7AI activity Vmax 1.11358 x 10-3 5.5679 x 10-4 2.78395 x 10-4 
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Figure 10. Role of CETP genotypes on LDL-C with ageing. To mimic an aged individual, a 2 fold 
increase in LDLr degradation, and a 2 fold decrease in NPC1L1 degradation, bile acid deconjugation, 
and CYP7AI activity was applied. For the youth analysis, the inverse of this protocol was conducted. A 
2 fold increase or decrease in CETP activity was then applied to each group. High (blue), normal 
(orange), and low (grey) CEPT activities examined. LDL-C measured at 1000 hours. 
 
 
6.0. Discussion  
 
We have updated a whole-body mathematical model of cholesterol metabolism. The updated 
model includes 96 additional mechanisms, and has been deposited in the BioModels database 
(MODEL1508170000). In contrast to the original model, this model is significantly less sensitive 
to cholesterol feeding, and can be categorised as a hypo- rather than hyper-responder to 
cholesterol ingestion. This finding is perhaps unsurprising in light of experimental evidence 
which suggests 62.5% of healthy normocholesterolaemic males exhibit a hypo-response to 
dietary cholesterol (Herron et al., 2003). Moreover, it is widely regarded that cholesterol 
metabolism adapts to cholesterol feeding by invoking two major compensatory regulatory 
mechanisms, these are an increase in cholesterol excretion, and a decrease in whole-body 
cholesterol biosynthesis (Quintao et al., 1971). When there is effective feedback control 
mechanisms this can result in dietary cholesterol failing to illicit a response in lipoprotein 
metabolism. For instance, McNamara et al. (1987) demonstrated using 12 week studies that 
both low and high levels of dietary cholesterol did not induce significant increases in mean levels 
of plasma total, LDL, or HDL cholesterol. Moreover, there was no relationship between baseline 
plasma cholesterol levels and sensitivity to a dietary cholesterol challenge (McNamara et al., 
1987).  
 
In our model, clearly LDL-C did not rise, however both hepatic free cholesterol and intestinal 
cholesterol increased significantly during high cholesterol feeding. In the seminal work by 
Quintao et al. (1971) it is postulated that cholesterol feeding in humans is primarily controlled 
by one compensatory mechanism – an increase in cholesterol excretion, but not bile acid 
excretion, our model helps to substantiate this claim. Intriguingly, the authors also suggest that 
when there is an accumulation of cholesterol in the body pools, the effects on lipoprotein levels 
are insignificant, regardless of the quantity of cholesterol absorbed. This appears to be the case 
in humans, as regulatory processes inhibit an increase in lipoprotein cholesterol when body 
pools accumulate. Model organisms have also shown that body pools of cholesterol can 
increase significant as a result of cholesterol feeding. Ohtani et al. (1990) suggest that, in 
hamsters, an additional 0.1% dietary cholesterol is enough to induce the accumulation of 
cholesterol in the liver through the chylomicron remnant pathway (Ohtani et al., 1990). Wang et 
al. (2010) also reported that concentrations of the hepatic total cholesterol increased ~4-fold by 
with a 1% increase in dietary cholesterol in rats (Wang et al., 2010). 
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Although the increases in the pools of cholesterol in our model, is similar to what has been 
reported experimentally, this could also suggest that our regulatory mechanisms may not be 
sufficiently adequate to deal with the excess cholesterol. One mechanism in this model that may 
need to be improved is the turnover of LDLr. In the updated model, an increase in dietary 
cholesterol, did not elicit a decrease in LDLr number. This contrasted with the previous model. 
This is an important point that needs to be emphasised, Hennessey et al. (1992) have 
demonstrated that a high intake of dietary cholesterol suppresses hepatic LDLr mRNA by 29% 
in cebus monkeys (Hennessy et al., 1992). Conversely, Spady and Cuthbert (1992) observed 
that rats on fed high levels of dietary cholesterol, did not exhibit suppressed hepatic LDLr activity 
despite a 350-fold increase in hepatic cholesterol ester levels (Spady and Cuthbert, 1992). More 
recently, Boone et al. (2011) found that LDLr expression in Sprague-Dawley rats was not altered 
by dietary cholesterol. There was also a significant increase in mean hepatic cholesterol and 
paradoxically a decrease in serum cholesterol (Boone et al., 2011). However, other studies in 
humans, such as Lichtenstein et al. (1993) demonstrate that the addition of dietary cholesterol 
(~1.5 eggs per/day) to a corn oil-diet,  can result in a significant increase in concentrations of 
total cholesterol (6%), LDL-C (8%), and HDL-C (7%), when compared to diets with low dietary 
cholesterol, in 14 middle-aged and older individuals. Studies such as this consolidate the view 
that LDLr activity is downregulated in response to cholesterol feeding. Despite the lack of 
sensitivity of lipoprotein metabolism to cholesterol feeding, our model was sensitive to increases 
in dietary SFA. This finding is in line with the experimental literature as dietary SFA has been 
shown clinically to have a more profound effect on cholesterol metabolism than dietary 
cholesterol (He and Fernandez, 1998; Herron et al., 2003).  
 
Large inter-individual differences in cholesterol metabolism, can in part be explained by genetic 
factors. For example, the I405V genotype is associated with longevity and reduced levels of 
CETP. This results in larger LDL-C and HDL-C particle size, in addition to reduced levels of 
LDL-C and increased HDL-C. This genotype is related to lower prevalence of hypertension, 
CVD, diabetes mellitus and metabolic syndrome (Atzmon et al., 2005; Barzilai et al., 2003). The 
role of a CETP genotype for reduced CETP, such as I405V, in reducing the risk of age-
associated disease, was consolidated with our simulations. It was demonstrated that increased 
CETP activity resulted in raised LDL-C in all age groups. Conversely, decreased CETP activity, 
led to a lower LDL-C in all age categories. Furthermore, the age-related increase in LDL-C was 
reduced with the presence of the I405V genotype (0.6% vs. 1.6%). Although it is important to 
note that a reduction in CETP levels and subsequent increase in HDL-C, either due to a genetic 
polymorphism or pharmaceutical intervention, has been associated with an increase in mortality 
rate (Barter et al., 2007; Zhong et al., 1996). It is therefore important that the findings from this 
work, and other studies, are fully evaluated before in vivo application. 
 
An important finding from our updated model was that the parameter values associated with the 
less well characterised aspects of cholesterol metabolism were particularly sensitive to changes 
in their values. Moreover, the cholesterol biosynthesis pathway, which has been well 
characterised, was a particularly robust part of the model. These findings from our local 
sensitivity analysis were supported by our global sensitive analysis, which demonstrated the 
increase in variation in LDL-C when unknown parameters were scanned, compared with known 
parameters. Therefore, we also have to consider the fact that the functional forms we have used 
to represent the interactions in our model may need further improvements, and that interactions 
may be due to many components of the model, such as RCT, lipoprotein dynamics and the 
enterohepatic circulation of bile acids, being poorly understood from a kinetic perspective.  
 
There are a number of aspects of the model that could be developed in the future. For example, 
when conjugated and unconjugated bile acid levels are in a steady state, the Vmax value for the 
deconjugation of bile acids was significantly lower than that reported in the experimental 
literature (reaction 45 Table A.3). For example, for the intestinal bacteria Clostridium 
perfringens, Bacteriodes fragilis and Lactobacilli have suggested Vmax values of 0.05, 38.4 and 
25.4mg/min/mg. However, a far lower Vmax value of 5 x 10-6 was used in the model (Gopal-
Srivastava and Hylemon, 1988; Lundeen and Savage, 1992; Stellwag and Hylemon, 1976). 
Areas such as cholesterol and bile acid synthesis could also be further developed to incorporate 
less well understood mechanisms that have not been included in the model. Furthermore, this 
model could be combined with other pre-existing models, or further developed to include other 
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compartments such as the gallbladder, or other interconnected metabolic pathways such as 
fatty acid or carbohydrate metabolism, or cortisol homeostasis. For example, cortisol is 
synthesised from cholesterol and is involved in provoking the breakdown of lipids, and a wide 
variety of other metabolites, therefore this model could be connected to a previously developed 
computational model of whole-body cortisol metabolism (Mc Auley et al., 2013; McAuley et al., 
2009). 
 
 
7.0. Conclusions 
In combination with our previous model, the updated model presented here emphasises the 
important role of intrinsic ageing in disrupting whole-body cholesterol metabolism. Constructing 
this model has revealed a number of findings. Firstly, simulations indicated that the model is a 
hypo-responder to cholesterol feeding, but is sensitive to simulated SFA feeding. Secondly, the 
model tentatively supports that genotypes such as I405V has a protective role in healthy ageing. 
The model also highlights the robustness of the cholesterol biosynthesis pathway, and suggests 
key areas where experimental work needs to focus in the future. This study has highlighted the 
need for kinetic data in several key areas of cholesterol metabolism, including RCT, lipoprotein 
dynamics and the enterohepatic circulation of bile acids. As these areas could provide potential 
therapeutic targets for lowering cholesterol, we believe that a more in depth understanding of 
this process could lead to novel interventions in the future. Finally, this work has demonstrated 
the important role computational systems biology has to play in improving our understanding of 
lipid metabolism and health-span. 
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